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A B S T R A C T
The renin-angiotensin system is involved in the progression of chronic renal disease of both diabetic and nondiabetic
origin. The angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have been demonstrated to re-
duce urinary protein excretion and attenuate the development of renal injury. This prospective, randomized, 12-month
study assessed the effects of ramipril (N=23) vs. valsartan (N=22) vs. combination of ramipril and valsartan (N=26) on
proteinuria, renal function and metabolic profile in 71 patients with nondiabetic proteinuria with normal or slightly im-
paired renal function. Monotherapy with ramipril or valsartan and combination of these two drugs significantly re-
duced proteinuria, serum creatinine, cholesterol and triglycerides as well as systolic and diastolic arterial blood pres-
sure. There was no significant difference among three study groups according to reduction of arterial blood pressure,
serum cholesterol and triglycerides. At one year, a significant reduction in serum creatinine was recorded in all three
study groups, whereas at 3 and 6 months a statistically significant reduction in serum creatinine was only observed in
patients on combination therapy. In addition, at 3 months the reduction of proteinuria was significantly greater in pa-
tients on combination therapy than in those on either monotherapy. These results indicated the combination therapy with
angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers to be more efficacious than either mono-
therapy in reducing proteinuria and serum creatinine level in the first 3 (proteinuria and serum creatinine) or 6 (serum
creatinine) months of treatment.
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Introduction
Many experimental and clinical data have shown that
the renin-angiotensin-aldosterone system (RAAS) has an
important role in the progression of nondiabetic renal
disease1–5. Of the various mechanisms that contribute to
renal function deterioration, hypertension has an impor-
tant role6. Angiotensin-converting enzyme (ACE) inhibi-
tors are more efficacious than conventional antihyper-
tensive drugs in delaying the progression of nondiabetic
renal disease. The renoprotective effects of ACE inhibi-
tors are independent of their systemic antihypertensive
action and are related to their antiproteinuric proper-
ties6–11. Despite administration of the maximal dose of
ACE inhibitors, the reduction of proteinuria varies among
different individuals, which can lead to different out-
comes. Even the patients that initially benefit from the
renoprotective properties of ACE inhibitors can deterio-
rate suddenly after a period of several years with impair-
ment of renal function. These findings suggest that mono-
therapy with ACE inhibitors is insufficient for complete
inhibition of the RAAS, which would prevent or halt the
progression of nondiabetic renal disease. It has been
shown that long-term therapy with ACE inhibitors does
not completely reduce angiotensin II production. Angio-
tensin II is also synthesized by chymase, a pathway not
regulated by ACE inhibitors. Because of the generation
of angiotensin II via non-ACE pathways, monotherapy
with an ACE inhibitor may result in suboptimal blockade
of the RAAS, even at maximally effective dose12,13. On the
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other hand, blocking the angiotensin II type 1 receptor
by angiotensin II receptor blocker (ARB) monotherapy
results in a compensatory rise in renin and consequently
in angiotensin II, with so far unknown consequences.
Combined therapy may decrease angiotensin II produc-
tion by inhibiting ACE activity and antagonize the ef-
fects of chymase-produced angiotensin II by blocking the
angiotensin II receptors. Some authors demonstrated
the progressive antiproteinuric and renoprotective ef-
fects of ACE inhibitor and ARB combination in patients
with nondiabetic proteinuric nephropathy14–18. We postu-
lated that complete inhibition of the RAAS would be
most beneficial in the management of progressive non-
diabetic renal disease. This might be achieved by dual
blockage with ARB and ACE inhibitors. In this prospec-
tive, randomized study we investigated the effect of ACE
inhibitor and ARB as monotherapy and combination
therapy on proteinuria and renal function in patients
with significant nondiabetic proteinuria.
Patients and Methods
This single-center, prospective, randomized, open-la-
bel, parallel group, comparative study evaluating renal
effects of therapy with ramipril, valsartan, or a combina-
tion of ramipril and valsartan included 75 patients with
nondiabetic renal disease and proteinuria 0.5 g/day. All
patients gave their written informed consent to partici-
pate in the study, which was approved by the local Ethics
Committee. Between February 2001 and May 2003, con-
secutive renal patients were screened for inclusion and
exclusion criteria. Patients were selected from our renal
department. Out of 75 patients screened, four were ex-
cluded from the study (two patients continued their dial-
ysis treatment, one patient withdrew from the study on
his own decision, and one patient died due to amyloi-
dosis). Inclusion criteria were age 18–60, nondiabetic
nephropathy established by patient history, physical ex-
amination, urinalysis, serum biochemistry tests and re-
nal biopsy (in most patients), and persistent proteinuria
0.5 g/day for a minimum of 3 months after first visit,
without evidence of urinary tract infection or heart fail-
ure. Patients were examined monthly by nephrologist for
the first 6 months, then every 3 months. At each visit,
physical examination and laboratory tests including blood
cell count, blood chemistry and urinalysis were done ac-
cording to standard laboratory procedures. The primary
endpoint of the study was to assess the glomerular filtra-
tion rate (GFR). GFR was determined at baseline, and at
3, 6 and 12 months using the Gault-Cockroft equation.
Secondary objectives were to assess long-term effects of
therapy with ramipril or valsartan or their combination
on the grade of proteinuria, arterial blood pressure, se-
rum creatinine, cholesterol and triglycerides. Exclusion
criteria were treatment with nonsteroidal anti-inflam-
matory drugs, renal failure, acute myocardial infarction
or stroke, severe uncontrolled hypertension, chronic pul-
monary disease, evidence or suspicion of renovascular
disease, obstructive uropathy, diabetes mellitus, cancer,
pregnancy, and infectious disease. Before enrollment, the
wash-out period was 4 weeks in patients taking ACE in-
hibitors or ARB and 2 weeks in patients without anti-
hypertensive treatment. Upon initial screening, patients
were randomized into three groups: patients initially
prescribed 5 mg/day ramipril (group 1); patients initially
prescribed 80 mg/day valsartan (group 2); and patients
treated with a combination of ramipril and valsartan in
equivalent dosage, depending on blood pressure values
(group 3). After 4 weeks, the dose of ramipril and valsar-
tan was increased to 10 mg and 180 mg once daily (only a
few patients), respectively, if blood pressure exceeded the
target systolic blood pressure of <140 mm Hg and dia-
stolic blood pressure of <90 mm Hg. Additional anti-
hypertensive agent other than ACE inhibitors or ARB
was urapidil, which was prescribed to achieve the target
blood pressure control. None of the patients were on cal-
cium channel blockers, which may affect proteinuria,
and all had well-controlled blood pressure during the
study period. Patients were also administered lipid-low-
ering drugs. All patients received advice on low sodium
diet. Patients with various glomerular diseases were ad-
ditionally treated with standard protocols as necessary.
Only five patients were receiving diuretics (2 patients on
ramipril, 2 patients on valsartan, and 3 patients on com-
bination therapy) to control edema; the dosage was re-
duced after several months of treatment as the edema
decreased. The study was conducted simultaneously in
all three groups and patients were evaluated at the be-
ginning of the study and at 3, 6 and 12 months of therapy
introduction by medical history, clinical examination,
blood pressure, proteinuria in 24-h urine sample, serum
creatinine, creatinine clearance, serum cholesterol and
triglyceride determination. At the end of baseline and
each active treatment phase, sodium excretion was as-
sessed in complete 24h urine collection. All patients were
given advice on low salt diet. Randomization codes were
kept in a sealed envelope for each study patient and were
opened upon completion of the inclusion criteria.
Statistics
Changes in daily urinary protein excretion, blood
pressure, serum creatinine, cholesterol and triglycerides
were analyzed by repeated-measures ANOVA. Baseline
characteristics were compared by Kruskal-Wallis and
Mann-Whitney tests, t-test and c2-test. Analyses were
done with the SPSS for Windows software. Statistical
significance was set at p<0.05.
Results
Patient characteristics at therapy introduction are
shown in Table 1. There was no significant difference
among the three therapeutic groups according to age,
systolic and diastolic blood pressure, level of proteinuria,
serum creatinine, creatinine clearance, serum triglycer-
ides and cholesterol. Renal biopsy was performed in 49
patients. Membranous nephropathy was present in 18,
focal segmental glomerulosclerosis in 12, IgA nephropa-
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thy in five, mesangioproliferative glomerulonephritis in
six, membranoproliferative glomerulonephritis in four,
minimal change disease in two patients, and post-strep-
tococcal glomerulonephritis and chronic glomerulone-
phritis in one patient each (Table 2). Twenty three pa-
tients were treated with ramipril, 22 with valsartan, and
26 with ramipril + valsartan. There was a statistically
significant correlation between follow-up periods (points
of measurement) and level of proteinuria in all three
groups. Proteinuria decreased with the length of treat-
ment (p<0.001 at 3 months; p<0.01 between 3 and 6
months; and p<0.001 between 6 and 12 months) (Figure
1). There was a statistically significant effect of treat-
ment on the level of proteinuria. At 3 months, patients
on combination therapy had a significantly greater de-
crease in proteinuria than patients on monotherapy
(F(2,60)=3,565; p<0.05). There was no statistically signifi-
cant difference in the mean sodium excretion among the
three patient groups. The mean serum creatinine de-
creased with time in all three groups (F(1.7,66)=8,125;
p<0.001) (Figure 2). There was no statistically signifi-
cant effect of the type of therapy on serum creatinine at
one year (F(2,66)=0,429; p>0.05), but a statistically signif-
icant correlation between the type of therapy and point
of measurement was recorded at 3 and 6 months (F(3.5,66)
=2,203; p<0.05). In the group on combination therapy, a
significant decrease in serum creatinine was recorded be-
tween successive points of measurement to up to 6
months (between therapy introduction and 3 months;
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TABLE 1
BASELINE CHARACTERISTICS AND LABORATORY FINDINGS (X±SD) OF 71 PATIENTS WITH NONDIABETIC PROTEINURIA
ACEI ARB ACE + ARB
Number of patients 23 22 26
Age (years) 46.3±16.4 47.4±16.9 46.1±18.3
Systolic blood pressure (mmHg) 138.7±19.8 145.7±26.8 148.5±19.4
Diastolic blood pressure (mmHg) 87.4±10.1 88.2±10.4 91.0±10.1
Proteinuria (g/day) 4.9±6.5 3.7±3.9 5.5±6.1
Creatinine (mmol/L) 109.6±97.6 104.5±45.8 111.7±79.8
Creatinine clearance (mL/min) 73.8±36.8 78.2±33.6 74.3±34.2
Triglycerides (mmol/L) 2.7±1.5 2.6±1.3 3.0±1.2
Cholesterol (mmol/L) 7.4±2.6 6.7±2.4 7.9±2.7
X – mean, SD – standard deviation, ACEI – angiotensin-converting enzyme inhibitor; ARB – angiotensin II receptor blocker
TABLE 2
RENAL BIOPSY HISTOPATHOLOGY (NUMBER OF PATIENTS)
ACEI ARB ACEI + ARB
Membranous glomerulonephritis 6 5 7
Focal segmental glomerulosclerosis 5 3 4
Membranoproliferative glomerulonephritis 2 1 1
Mesangioproliferative glomerulonephritis 2 3 1
Post streptococcal glomerulonephritis 0 0 1
IgA nephropathy 2 2 1
Minimal change disease 0 1 1
Nephronophthisis 1 0 0
Total 18 15 16
ACEI – angiotensin-converting enzyme inhibitor; ARB – angiotensin II receptor blocker
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Fig. 1. Mean 24-hour protein excretion at four points of measure-
ment in three patient groups. AT1 antagonist – angiotensin II re-
ceptor blocker, ACE – angiotensin converting enzyme.
between 3 and 6 months; and between 6 and 12 months,
p<0.05 all). In patients on monotherapy, only the differ-
ence in serum creatinine measured at therapy introduc-
tion and at one year was statistically significant (p<
0.01), whereas the difference in serum creatinine be-
tween therapy introduction and 3 months, and between
3 and 6 months did not reach statistical significance
(p>0.05). At follow-up measurements, the mean crea-
tinine clearance increased from the baseline value, but
the difference was not statistically significant (main ef-
fect of repeat measures F(3,66)=1,33; p>0.05; main effect
of therapy (F(2,68)=444.87; p>0.05) (Figure 3). There was
no significant difference among study groups according
to baseline systolic blood pressure. Systolic blood pres-
sure decreased significantly with the time of measure-
ment (F(1.8,68)=29.425; p<0.001) (Figure 4). Systolic blood
pressure decreased continuously with time in all three
groups, except for the period between 3 and 6 months
(p<0.001 between therapy introduction and 3 months;
p>0.05 between 3 and 6 months; and p<0.05 between 6
and 12 months). The type of therapy had no statistically
significant effect on the systolic blood pressure decrease
(F(2,68)=0.623; p>0.05). There was no significant differ-
ence among study groups according to baseline diastolic
blood pressure. Diastolic blood pressure decreased signif-
icantly with the time of measurement in all three patient
groups (F(2.3,68)=37.831; p<0.001) (Figure 5). Therapeu-
tic effect appeared to have reached maximum at 6 months
in all three groups (p<0.001 between therapy introduc-
tion and 3 months; p<0.05 between 3 and 6 months; and
p>0.05 between 6 and 12 months), with no statistically
significant difference among the groups (F(2,68)=0.282;
p>0.05). Thus, both systolic and diastolic blood pressure
significantly decreased with time in all 3 groups. In all
three groups, the peak therapeutic effect on diastolic
blood pressure was achieved at 6 months and on systolic
blood pressure at one year (Figures 4 and 5). A statisti-
cally significant decrease was recorded in total serum
cholesterol (F(1.9,68)=43.956; p< 0.001) and triglycerides
(F(2.5,68)=30.399; p<0.001) over four points of measure-
ment, however, without statistically significant differ-
ences among the three therapeutic groups. Two patients
treated with ramipril had dry irritating cough lasting for
up to 3 months of therapy introduction, then it resolved
spontaneously. No side effects were observed in the other
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Fig. 2. Mean serum creatinine values at four points of measure-
ment in three patient groups. AT1 antagonist – angiotensin II re-
ceptor blocker, ACE – angiotensin converting enzyme.
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Fig. 3. Mean creatinine clearance values at four points of mea-
surement in three patient groups. AT1 antagonist – angiotensin
II receptor blocker, ACE – angiotensin converting enzyme.
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Fig. 4. Mean systolic blood pressure at four points of measure-
ment in three patient groups. AT1 antagonist – angiotensin II re-
ceptor blocker, ACE – angiotensin converting enzyme.
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Fig. 5. Mean diastolic blood pressure at four points of measure-
ment in three patient groups. AT1 antagonist – angiotensin II re-
ceptor blocker, ACE – angiotensin converting enzyme.
two patient groups. The more so, neither did plasma po-
tassium level change as a result of treatment throughout
the study (data not shown).
Discussion
Proteinuria is a significant independent determinant
of the progression of chronic kidney disease. There is a
strong association between the level of proteinuria and
renal function decline6,9,19. A large number of experimen-
tal studies have provided compelling evidence that pro-
teins filtered by diseased glomeruli induce harmful ef-
fects on glomerular and tubulointerstitial structures. An
increased renal synthesis of angiotensin II has been dem-
onstrated in proteinuric renal diseases. The increased
synthesis of angiotensin II plays a central role in activat-
ing the transcription factor NF-kb and increasing the ex-
pression of several cytokines, cell adhesion molecules
and growth factors. One of them is the transforming
growth factor-b (TGF-b)20. TGF-b has a central role in re-
nal scarring, stimulating the synthesis of matrix proteins
and increased production of protease inhibitors21–24. An-
giotensin II blockade by ACE inhibitors or ARB results in
a decrease in TGF-b expression and matrix accumu-
lation25,26. Any therapeutic intervention to reduce the
level of proteinuria should have an important beneficial
effect on the progression of proteinuric nephropathies.
In order to test whether the antiproteinuric effect of a
combination of ACE inhibitors and ARB is superior to
ACE inhibitors or ARB alone in patients with nondia-
betic proteinuric nephropathy, we compared the effects
of three different drug regimens, i.e. the ARB valsartan
combined with ACE inhibitor ramipril versus ramipril or
valsartan alone. The combination of ACE inhibitor and
ARB proved significantly better than either individual
drug in reducing proteinuria. This result is in agreement
with the last large meta-analysis study27. At 6-month fol-
low-up, the group on combination therapy showed a sig-
nificant decrease in serum creatinine as compared to pa-
tients on monotherapy. In the group of patients on com-
bination therapy, creatinine clearance showed continu-
ous but statistically non-significant increase from the
start to the end of the study, probably due to small sam-
ple size. In each treatment group, there were some pa-
tients on immunosuppressive drugs (12 patients on ACE
inhibitors, 11 patients on ARB, and 12 patients on ACE
+ ARB), and we suppose that the improvements in
proteinuria and glomerular filtration were attributable
to immunosuppression. The COOPERATE trial, pow-
ered for renal outcome as a primary endpoint, reports
that the combination group had slower rates of decline in
renal function than patients on individual therapy; un-
fortunately, the results are widely viewed as being un-
reliable28,29 and additional, properly conducted prospec-
tive trials are needed to answer the question of the
efficacy of combination therapy on the chronic kidney
damage progression. Most recently, the results of the
ONTARGET trial, which compared ACE inhibitor rami-
pril and ARB (telmisartan) in high-risk patients, showed
that the incidence of primary renal outcome (a composite
of dialysis, doubling of serum creatinine and death) was
comparable between two drugs, and also the combina-
tion of both drugs at maximally tolerated dose achieved
no further benefits on renal function and was associated
with more adverse effects than monotherapy30. However,
this study is not entirely comparable to our study, be-
cause the minority of patients in ONTARGET study had
proteinuria (17.1% at baseline), and also patients with
diabetes and possible diabetic kidney disease were in-
cluded. Some studies, in agreement with our study sho-
wed the beneficial effects of combination therapy with
both ACE inhibitors and ARB, in reducing overt pro-
teinuria more effectively than single-agent therapy in pa-
tients with nondiabetic nephropathy14–17, which could be
associated with retarding of renal disease progression.
However, it is recommended that patients receiving dual
therapy, if clinically justified should be monitored closely
for potential adverse effects31,32.
Conclusion
Study results indicated that treatment with a combi-
nation of ACE inhibitor and AT1 receptor blocker may be
better in patients suffering from nondiabetic renal dis-
ease with significant proteinuria than treatment with ei-
ther drug alone. This method of treatment does not only
provide good blood pressure control, but also appears to
slow the progression of renal failure and to decrease
proteinuria.
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U^INCI RAMIPRILA I VALSARTANA NA PROTEINURIJU I BUBRE@NU FUNKCIJU U BOLESNIKA
S NEDIJABETI^KOM PROTEINURIJOM
S A @ E T A K
Reninsko-angiotenzinski sustav uklju~en je u progresiju i dijabeti~ke i nedijabeti~ke kroni~ne bubre`ne bolesti. Po-
kazalo se da inhibitori angiotenzin-konvertiraju}eg enzima i blokatori receptora angiotenzina II smanjuju proteinuriju
i usporavaju razvoj bubre`nog o{te}enja. U ovom prospektivnom, randomiziranom, 12-mjese~nom istra`ivanju uspore-
|ivani su u~inci ramiprila (N=23 bolesnika), valsartana (N=22) i kombinacije ramiprila i valsartana (N=26) na pro-
teinuriju, bubre`nu funkciju i metaboli~ki profil u 71 bolesnika s nedijabeti~kom proteinurijom s normalnom ili blago
o{te}enom bubre`nom funkcijom. Monoterapija ramiprilom i valsartanom i kombinacija ova dva lijeka zna~ajno su
smanjili proteinuriju, serumski kreatinin, kolesterol i trigliceride kao i sistoli~ki i dijastoli~ki krvni tlak. Nije bilo sta-
tisti~ki zna~ajne razlike izme|u 3 skupine u smanjenju krvnog tlaka, serumskog kolesterola i triglicerida. Nakon 12
mjeseci, zna~ajno smanjenje serumskog kreatinina zabilje`eno je u sve tri skupine bolesnika, dok je nakon 3 i 6 mjeseci
statisti~ki zna~ajno smanjenje serumskog kreatinina opa`eno samo u skupini bolesnika na kombinacijskoj terapiji.
Osim toga, nakon 3 mjeseca smanjenje proteinurije bilo je statisti~ki zna~ajno ve}e u skupini na kombinacijskoj terapiji,
nego u skupinama bolesnika s monoterapijom ramiprilom i valsartanom. Ovi rezultati pokazuju da je kombinacijska
terapija inhibitorom angiotenzin-konvertiraju}eg enzima i blokatora receptora angiotenzina II u~inkovitija od mono-
terapije u smanjenju proteinurije i serumskog kreatinina nakon 3 mjeseca i smanjenju serumskog kreatinina nakon 6
mjeseci lije~enja.
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